Inspections and Audits

FDA and EMA Hit Zhejiang Huahai Over GMP Violations

The FDA placed valsartan manufacturer Zhejiang Huahai on an import alert Friday and the EMA issued a noncompliance statement barring Europe’s drugmakers from using the company’s API in their blood pressure products. Read More